U.S., Feb. 1 -- ClinicalTrials.gov registry received information related to the study (NCT06802835) titled 'EGFR Antibody Combined With PD-1 Inhibitor and Chemotherapy in R/M Nasopharyngeal Carcinoma' on Jan. 25.
Brief Summary: This is a prospective, single-arm, phase II clinical trial. The purpose of this study is to evaluate the efficacy and adverse effect of EGFR antibody combined with programmed death 1 (PD-1) antibody and chemotherapy in recurrent/metastatic nasopharyngeal carcinoma patients.
Study Start Date: Feb., 2025
Study Type: INTERVENTIONAL
Condition:
Nasopharyngeal Cancinoma (NPC)
Recurrent Nasopharynx Carcinoma
Metastatic Nasopharyngeal Carcinoma
Intervention:
DRUG: EGFR Antibody
6 cycles for combined therapy. Maintena...